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Introduction: Pre-operative restaging CT scans are often performed routinely following neoadjuvant
chemoradiotherapy for locally advanced rectal cancer. There is a paucity of data on the utility of this
common practice. We sought to determine how often restaging CTs identiﬁed disease progression or
regression that altered management. Methods: We performed a single-institution retrospective study.
From 2007 to 2011, 182 patients had newly-diagnosed, non-metastatic rectal adenocarcinoma, of which
96 were surgical candidates with clinical stage II/III disease. Ninety-one of these patients (95%)
completed neoadjuvant chemoradiation. Results: Eighty-three out of 91 patients (91%) had restaging CTs.
Four patients (5%) had new lesions suspicious for distant metastasis (2 lung, 2 liver) on restaging CT scan
reports (1 of these was present on initial staging CT but not reported). All 4 patients had node-positive
disease. In no case did restaging CT result in a change in surgical management. Discussion: Because of
the ﬁnancial costs and established risks of intravenous contrast and cumulative radiation exposure, it
may be advisable to take a more selective approach to preoperative imaging. Larger, prospective studies
may enable identiﬁcation of an at-risk cohort who would beneﬁt most from restaging CT. Conclusion:
Routine restaging CT scans are low yield in the management of locally advanced rectal cancer.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
In the United States, over 40,000 new cases of rectal cancer are
diagnosed each year [1]. For patients with newly-diagnosed rectal
adenocarcinoma, the role of initial staging computed tomographytal Surgery, UMass Memorial
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[2e4]. CT scans are 75e100% sensitive for detection of distant
colorectal cancer metastases [5,6]. For local staging of the primary
tumor, CT is less sensitive than MRI or endorectal ultrasound;
however, it has been shown to have 55e70% accuracy in identifying
nodal disease, and 73% accuracy for T staging [7e9]. Twenty percent
of patients with rectal cancer will have metastatic disease at the
time of presentation [10]. Five-year overall survival for metastatic
rectal cancer is only 6%, and only 20e30% of this group is eligible for
metastasectomy with curative intent [11e13]. Accurate staging of
both local and distant disease is therefore instrumental in
providing appropriate care for patients with rectal cancer.
Most patients with locally advanced (clinical stage IIeIII) mid or
low rectal cancer who are surgical candidates receive neoadjuvant.
181 newly diagnosed, 
nonmetastatic rectal cancer
96 clinical stage II-III61 clinical stage I 25 exlcuded:
10 declined surgery
9 not surgical candidates
6 had surgery elsewhere
5 no chemoXRT:
3 had prior XRT
1 was not candidate 
1 did not tolerate Rx
91 completed chemoXRT 
8 not restaged 83 restaged
Fig. 1. Patient subsets.
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resection [14]. Despite a lack of supportive evidence, it is common
practice at many institutions to obtain routine restaging CT scans of
the chest, abdomen, and pelvis following completion of neo-
adjuvant therapy. Restaging CT scans have the potential to impact
management by identifying new distant metastases or local disease
regression or progression. Detection of new distant metastasesmay
alter management by prompting the use of additional chemo-
therapy, synchronous or staged metastasectomy, or non-operative/
palliative care.
Local disease progression may suggest the need for a more
extended resection including en bloc resection of involved pelvic
organs or partial sacrectomy, or the tumor may be deemed unre-
sectable. Alternatively, the tumor may regress and more deﬁned
tissue planes predict a less extended resection. Several studies have
compared the efﬁcacy of various imagingmodalities in determining
the primary tumor response to neoadjuvant therapy, and the ca-
pacity to predict ﬁnal pathologic staging. The primary limitation,
which is common to all imaging modalities, is the inability to
distinguish treatment-related ﬁbrosis and edema from tumor [15];
nevertheless, CT has been shown to effectively exclude advanced T
stages (ypT4) and circumferential resection margin involvement,
with high speciﬁcity for N staging [16].
Current National Comprehensive Cancer Network (NCCN) [17]
and American Society of Colon and Rectal Surgeons (ASCRS) [18]
practice guidelines do not provide recommendations on the
appropriateness of restaging CT scans or their role in the routine
care of patients with locally advanced rectal cancer. Although
restaging CTs are a common practice, minimal literature exists that
either supports or refutes the use of these scans. There are no
deﬁnitive data on the actual diagnostic yield of restaging CT scans
in patients receiving neoadjuvant 5-FU based chemotherapy and
pelvic irradiation for locally advanced rectal cancer.
CT scans have inherent risks for the patient and increase overall
healthcare costs. Contrast-induced nephropathy and allergic re-
actions to iodinated contrast can be observed in patients under-
going CT imaging [19e21]. Moreover, there is an increasing
awareness about the negative consequences of cumulative radia-
tion exposure, such as an increased risk of malignancy [22]. In
addition, nonspeciﬁc ﬁndings on CT scans often compel clinicians
to pursue additional, more costly work-up. In the era of bundled
payments, streamlining patient care by minimizing low-yield
diagnostic studies has never been more important.
The primary aim of this study was to determine how frequently
ﬁndings on routine restaging CT scans altered surgical manage-
ment. We hypothesized that routine restaging CT scan following
the completion of neoadjuvant chemoradiation did not change the
treatment of rectal cancer with regard to the surgical plan.
2. Methods
Approval to initiate the study was obtained from our Institu-
tional Review Board. The UMass-Memorial Tumor Registry was
queried to identify all patients with newly diagnosed biopsy-
proven rectal adenocarcinoma from 2007 through 2011. The Elec-
tronic Medical Record (EMR) for each patient was reviewed by an
experienced clinician. Demographic data included patient age and
gender. Clinical data included preoperative clinical stage; endor-
ectal ultrasound, MRI, and CT scan reports; initial carcinoembryonic
antigen (CEA) level; type and duration of chemoradiotherapy; type
of resection performed; surgeon specialty (colon and rectal sur-
geon, surgical oncologist, or general surgeon); intraoperative
ﬁndings; ﬁnal pathologic stage; length of postoperative follow-up;
local and distant disease recurrence; and mortality. Data were ob-
tained from ofﬁce and inpatient consult notes, operative reports,radiology and pathology reports. Patients were excluded based on
the following criteria: metastases at diagnosis, recurrence of pre-
vious rectal cancer, not surgical candidates or refusal of surgery, or
surgery performed at an outside institutionwith incomplete data in
our EMR.
All patients included in the analysis had staging CT scans of the
chest, abdomen, and pelvis performed at the time of diagnosis. A
subset of patients also had PET scan at the time of diagnosis. Neo-
adjuvant treatment consisted of standard concurrent 5-FU based
chemotherapy and 50.4 Gy pelvic radiation. “Re-staging” CT scans
were performed following documented completion of chemo-
radiotherapy, prior to surgery. In some cases, restaging PET was also
performed. Transanal excision included conventional full-thickness
resection as well as Transanal Endoscopic Microsurgery (TEM); low
anterior resection (LAR) included both laparoscopic-assisted and
open procedures, with and without diverting loop ileostomy.
Abdominoperineal resection (APR) included laparoscopic-assisted
procedures and conventional open procedures. Final pathologic
stage is documented according to American Joint Committee on
Cancer (AJCC) 6th edition (pre-2010) and 7th edition (from 2010-
on) [23,24].3. Results
A total of 182 patients were identiﬁed with a new diagnosis of
nonmetastatic rectal adenocarcinoma (mean age 64, 56% male;
Fig. 1). Eighty-six patients were excluded from further review for
the following reasons: 61 patients had clinical stage I disease and
did not receive neoadjuvant therapy, 10 declined surgery, 9 were
not surgical candidates due to medical co-morbidities, and 6 had
surgery at other institutions.
Ninety-six patients were surgical candidates with clinical stage
IIeIII disease. Three patients did not receive radiation therapy
because they had prior pelvic radiation for prostate cancer, and 1
patient did not receive any neoadjuvant treatment due to throm-
bocytopenia. Of the 92 remaining patients (mean age 60, 61%male),
all completed neoadjuvant chemoradiotherapy except for 1 patient
who discontinued chemotherapy early due to toxicity. Of the 91
patients who completed neoadjuvant therapy, 84 (92%) had their
resection performed by a board-certiﬁed colon and rectal surgeon;
4 (4%) were performed by a general surgeon, and 3 (3%) by a sur-
gical oncologist.
Following completion of neoadjuvant chemoradiotherapy, 83 of
the 91 patients (91%) had restaging CT scans of the chest, abdomen,
and pelvis. The mean duration between initial staging and restag-
ing CT scans was 106 days (range 76e169 days). There were no
documented iatrogenic injuries (such as contrast-induced allergy
Table 1
Patient Characteristics. Pre-treatment CEA data was available for 90% of patients.
*Other denotes use of CT scan, rigid proctoscopy, or digital rectal exam to determine
local staging. **Clinical node positivity rate was determined by evidence of positive
nodes on either U/S or MRI; patients who did not have these modalities were
excluded from this analysis.
Restaged
(N ¼ 83)
Not restaged
(N ¼ 8)
Overall
(N ¼ 91)
Mean age 61 57 60
% Male 60 75 61
Mean pre-treatment
CEA ng/mL (range)
7.1 (0.2e65) 4.56 (1.2e13.2) 6.87 (0.2e65)
Pre-treatment PET (%) 34 50 35
Local staging modalities (%)
U/S only 61 63 62
MRI only 7 0 6
U/S and MRI 10 12 10
Other* 22 25 22
Clinical node positivity (%)** 48 38 47
Table 2
Type of resection performed for restaged and not-restaged patients. LAR ¼ low
anterior resection; APR ¼ abdominoperineal resection.
Procedure Restaged Not restaged Total (%)
Transanal 3 0 3 (3)
LAR 52 6 58 (64)
APR 28 2 30 (33)
Total 83 8 91
83 restaged (91%)
79 (95%)
no mets
4 (5%) 
new mets
83 surgical resection:
• 76 no intraop mets
• 3 transanal excisions
8 not restaged (9%)
8 surgical resection:
• 8 no intraop mets
• 0 intraop mets
91 completed chemoXRT 
Fig. 2. Management and operative ﬁndings of staged and not-restaged patients. Four
of the restaged patients (5%) had lesions suspicious for new metastasis (2 liver, 2 lung).
Three restaged patients had transanal excision and therefore no operative abdominal
exploration was performed. None of the not-restaged patients had intraoperative
metastasis.
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had restaging PET scans (all negative for metastasis). Table 1 dis-
plays the patient characteristics of restaged and not-restaged pa-
tients. The not-restaged group was too small (8 patients) for
relevant statistical comparison to the restaged group.
Table 2 shows the breakdown by procedure according to pres-
ence or absence of restaging CT scans. Of the 83 restaged patients,
52 had LAR (63%), 28 had APR (34%), and 3 had transanal/TEM re-
sections (3%). Of the 8 patients who were not restaged, 6 had LAR
(75%) and 2 had APR (25%).
Four restaged patients (5%) were found to have new lesions
likely representing metastasis on restaging CT scan reports. The
clinical characteristics and outcomes of these patients are sum-
marized in Table 3. Two patients had new lesions suspicious for
pulmonary metastases. Two patients had new liver lesions. Of note,
one of these patients had an initial staging CT read as negative; a
different radiologist (from the same institution) read the restaging
scan and noted the presence of a liver lesion, which he recognized
was present on the initial scan. According to the report on the
restaging CT, the lesion increased in size from 0.8 cm to 1.3 cm.
These cases were all discussed in our multidisciplinary GI tumor
board, and in all four instances, the decision was made to proceedTable 3
Clinical characteristics and outcomes of the 4 patients who had new metastases identiﬁ
lesions were not FDG-avid. **Denotes patient for whom the initial staging CT report was n
the size of a 0.8 cm liver lesion to 1.3 cm.
Site of metastasis Restaging CT report Initial CEA (ng/mL) Operation
Lung Solitary 6 mm nodule 7 LAR
Lung Bilateral nodules* 4.5 LAR
Liver 1 cm R posterior lobe lesion 2 LAR
Liver** 1.3 cm R liver dome lesion 3.7 LAR, liverwith the planned surgical resection of the primary tumor. All 4
patients had node-positive disease on ﬁnal pathology.
Surveillance imaging for the patient with the solitary lung lesion
revealed new lung and liver lesions consistent with metastases at 6
months postoperative follow-up, prompting treatment with addi-
tional chemotherapy (FOLFIRI regimen) and was then lost to follow
up (care was transferred to a different institution). The patient with
new bilateral pulmonary nodules had eventual progression of
pulmonary disease 18 months postoperatively, and was started on
chemotherapy. The lung lesions were not amenable to resection.
She subsequently developed brain metastases and underwent
palliative radiation. She died 13 months after surgery. As for the
ﬁrst patient with the liver lesion identiﬁed on restaging CT, the
lesion was not accessible for simple biopsy or wedge resection
during LAR. Postoperatively, the lesion was conﬁrmed to be
adenocarcinoma on CT-guided biopsy. The patient was started on
FOLFOX and Avastin, and underwent staged partial hepatectomy 5
months after his rectal cancer resection. He was alive 13 months
postoperatively (at last follow-up). The second patient with a liver
metastasis identiﬁed on restaging CT had multiple liver metastases
at laparotomy. The dominant mass was biopsied, conﬁrming met-
astatic adenocarcinoma. Postoperative surveillance imaging iden-
tiﬁed new pulmonary metastases. He had multiple co-morbidities
and experienced a cerebellar infarct 1 month postoperatively; he
was deceased at 4 months postoperatively.
None of the restaged patients had local progression of disease
identiﬁed on CT that prompted a change in the surgical work-up or
extent of resection. Three of the restaged patients had transanal
excisions, and therefore never had metastases ruled outed on restaging CT scan. *This patient underwent preoperative PET scan and these
egative; restaging CT (read by a different radiologist) reported an interval increase in
Final pathology Outcome/follow-up
T3N1 Chemotherapy; alive at 6 months follow-up
T2N2 Chemotherapy; palliative radiation for brain
metastases; deceased at 60 months follow-up
T3N2 Chemotherapy and staged hepatectomy; alive
at 13 months follow-up
biopsy T3N2 Liver biopsy positive for adenocarcinoma; deceased
at 4 months follow-up after CVA
Table 5
Follow-up and outcomes for restaged and not-restaged patients.
Restaged
N ¼ 83
Not restaged
N ¼ 8
Overall
N ¼ 91
Median follow-up (months) 31 33 30
Local recurrence (%) 1 (1) 0 1 (1)
Distant metasasis (%) 7 (8) 0 7 (7.6)
Deaths (%) 5 (6) 0 5 (5.5)
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intraoperative metastases were identiﬁed (Fig. 2).
Table 4 shows ﬁnal pathologic stage data for the restaged pa-
tients. Thirteen patients had a complete response (16%), 24 stage I
(29%), 12 stage II (14%), 30 stage III (36%), and 4 stage IV (5%).
Follow-up, recurrence, and mortality data are shown in Table 5.
Overall median followupwas 30months. Local recurrence occurred
in one restaged patient at 68 months and was treated with en bloc
resection; she is alive at 72 months follow-up. The overall rate of
distant metastasis was only 7.6% (7 patients, not including the 4
patients with metastases identiﬁed on restaging CT), and all of
these were in the restaged group. Mean time to recurrence was 43
months postoperatively. There were 5 deaths in the restaged group
(2 of which had new metastases diagnosed on restaging CT) and
none observed in the not-restaged group.
Additional chart review was performed to determine whether
the characteristics of the 8 patients who were not restaged were
different from the 83 patients whowere. Two of the 8 patients who
were not restaged had resections performed by non-colorectal
surgeons, 1 declined restaging scans, 3 had rigid proctoscopy or
ﬂexible sigmoidoscopy to re-evaluate the primary, and in 2 cases
the reason could not be determined.4. Discussion
The ﬁndings of this study suggest that the routine practice of
obtaining restaging CT scans of the chest, abdomen, and pelvis
following neoadjuvant therapy for locally advanced rectal cancer is
low yield and does not alter surgical management. Only 4 out of 83
(5%) restaging CT scans identiﬁed lesions suspicious for distant
metastases. In these cases, the surgical plan remained unaltered,
although these ﬁndings may have impacted decisions regarding
adjuvant chemotherapy and subsequent surgical interventions. In
no case did restaging CT scans identify local disease progression
prompting a change in surgical work-up or management, such as
the need for insertion of ureteral stents, en bloc resection of
contiguous organs, or determination of unresectability. No new
intraoperative metastases were found in the 8 patients who were
not restaged.
This study is unique in that it explores the diagnostic yield of
routine restaging CT scans following neoadjuvant chemoradiation
for rectal cancer in an academic cancer center that routinely per-
forms these scans. In a related study, Ayez et al. concluded that
restaging CT scans are a valuable component of the treatment al-
gorithm, having identiﬁed treatment-altering ﬁndings in 12% of
cases [25]. There are several important differences between these
two studies. Over a 10-year period, Ayez et al. identiﬁed over 2000
patients who underwent treatment with neoadjuvant radiotherapy
(with or without chemotherapy) for locally advanced rectal cancer.
Of these patients, only 143 patients underwent restaging CT scans,
suggesting the possibility of signiﬁcant selection bias. Patients sentTable 4
Final pathologic stage by type of resection for restaged patients. CR ¼ complete
pathologic response. LAR ¼ low anterior resection. APR ¼ abdominoperineal
resection. In this analysis, the 3 patients who underwent transanal excision were
considered to have M0 disease.
Final stage Transanal LAR APR Total (%)
CR 0 6 7 13 (16)
I 3 17 4 24 (29)
II 0 7 5 12 (14)
III 0 18 12 30 (36)
IV 0 4 0 4 (5)
Total 3 52 28 83for restaging scans may inherently have been at higher risk for
disease progression. Additionally, of the 143 restaged patients in
their study, 46 patients (42%) received radiotherapy only (no
chemotherapy). This may account for the high number of patients
(11%) with newmetastases on restaging CT thus altering treatment
strategy in 13 of 15 patients (87%). This ﬁnding contrasts with the
lower rate of disease progression (4 of 83 patients or 5%) demon-
strated in our study and with no subsequent changes in surgical
management.
A more recent study by Jaffe et al. found similar results to our
study. In a cohort of 88 patients with localized rectal cancer,
restaging CT scan did not identify any new metastases [26]. This
study did not provide data on initial staging modalities, patient
characteristics, follow-up, and rate of recurrence, nor did it assess
for local disease progression. Additionally, only 88 of 200 patients
(44%) had restaging CT scans performed, again introducing the
possibility of selection bias.
Our single institution, retrospective study is limited by a small
sample size that renders it underpowered to reveal more subtle
differences in the restaged and not-restaged groups. Data on
restaging CT scans were based entirely on radiology reports from
our own institution and referring facilities, and the original CT scan
images were not re-reviewed by an independent, blinded radiolo-
gist. Because three of the restaged patients had transanal excisions,
the presence or absence of intraabdominal metastasis could not be
determined intraoperatively for these patients.
Further, in this series, we retrospectively report the decisions of
our own multidisciplinary group in proceeding directly to surgery
in the four patients who had new suspicious lesions identiﬁed on
restaging CT. As there currently is no consensus on the manage-
ment of synchronous liver metastases, it is understandable that
other institutions have different management practices for such
patients (such as simultaneous liver and rectal resection, or a “liver-
ﬁrst” strategy), and that could potentially have led to a different
conclusion for this subgroup [27,28]. Nevertheless, this subgroup
was small, only 4 out of 83 patients (5%), which suggests that,
despite the management decisions made on these patients, the
overall practice of routine restaging CT is low yield. Lastly, because
patients were selected from 2007 to 2011, more long-term follow-
up and survival data are not yet available.
Our study suggests that, following neoadjuvant chemotherapy
for locally advanced rectal cancer, routine restaging CT scans are of
low diagnostic yield for most patients. These ﬁndings suggest that a
standardized and streamlined approach to the management of
rectal cancer, designed tominimize low yield radiographic imaging,
may not only reduce health care costs, but also decrease the risks to
patients. While none of our patients experienced an iatrogenic
injury directly related to CT scans, these tests are not without risk.
CT scans with intravenous contrast are associated with risk of
contrast-induced nephropathy, particularly in patients with un-
derlying renal insufﬁciency [21]. Furthermore, allergic reactions to
iodinated contrast occur in roughly 3% of scans and can be life-
threatening [29]. The risk of radiation from one additional scan is
relatively small, but cancer patients often undergo multiple scans
throughout their treatment course, so any unnecessary exposure
J.S. Davids et al. / International Journal of Surgery 12 (2014) 1295e1299 1299should be minimized. According to NCCN practice guidelines for
diagnosis and surveillance of rectal cancer, a 5-year survivor of
rectal cancermay have asmany as 6 CT scans of the chest, abdomen,
and pelvis from the time of diagnosis [17]. With nearly 50% of node-
positive cancer patients alive at 10 years, this is a legitimate
concern.
Future directions of this work include performing a larger,
prospective study, which would allow for additional survival data
and cost analysis. Such additional investigation may allow for
identiﬁcation of a high-risk cohort (such as node-positive disease
or bulky primary) which may beneﬁt more from restaging, thereby
favoring a selective, as opposed to a routine approach. This work
ultimately has the potential to impact practice guidelines for rectal
cancer, which currently do not address restaging CT scans due to
the paucity of data on this topic. In the era of accountable care, it is
becoming increasingly important to avoid costly diagnostic studies
that are unlikely to affect management. For diseases as complex as
rectal cancer, a streamlined approach to treatment will enable
multidisciplinary teams to provide optimal care while reducing the
overall burden on the healthcare system and risk to patients.
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